CareDx, Inc. (CDNA)
| Market Cap | 2.58B +264.1% |
| Revenue (ttm) | 458.09M +34.4% |
| Net Income | 111.01M +90.9% |
| EPS | 2.12 +112.5% |
| Shares Out | 51.73M |
| PE Ratio | 23.48 |
| Forward PE | 42.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,178,533 |
| Open | 51.50 |
| Previous Close | 52.36 |
| Day's Range | 49.60 - 52.38 |
| 52-Week Range | 12.37 - 53.67 |
| Beta | 2.42 |
| Analysts | Buy |
| Price Target | 52.33 (+5.1%) |
| Earnings Date | Jul 30, 2026 |
About CDNA
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about dist... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price target is $52.33, which is an increase of 5.10% from the latest price.
News
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of indu...
CareDx price target raised to $60 from $45 at BTIG
BTIG raised the firm’s price target on CareDx (CDNA) to $60 from $45 and keeps a Buy rating on the shares. CareDx delivered a solid Q2 beat-and-raise, with the Medicare…
Craig-Hallum ups CareDx to Buy, says guidance feels conservative
As previously reported, Craig-Hallum analyst Bill Bonello upgraded CareDx (CDNA) to Buy from Hold with a price target of $64, up from $35. With shares up 132% year-to-date, the firm…
CareDx upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum upgraded CareDx (CDNA) to Buy from Hold with a price target of $64, up from $35.
CareDx Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 52% to $132M, with strong gains in testing services and successful integration of NavDx. Raised 2026 guidance to $490–$500M revenue and $66–$78M adjusted EBITDA, driven by growth in transplant and specialty oncology. Clinical and reimbursement milestones support continued expansion.
CareDx Earnings release: Q2 2026
CareDx released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
CareDx Quarterly report: Q2 2026
CareDx has published its Q2 2026 quarterly earnings report on July 30, 2026.
CareDx Slides: Q2 2026
CareDx has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
CareDx raises FY26 revenue view to $490M-$500M, consensus $455.9M
For the full year 2026, CareDx (CDNA) now expects revenue to be in the range of $490 million to $500 million, compared to the $447 million to $465 million range…
CareDx reports Q2 EPS 37c, consensus 23c
Reports Q2 revenue $132M, consensus $114.1M. “We have transformed CareDx (CDNA) into a differentiated precision molecular diagnostics company with a unique set of core competencies that position us fo...
CareDx Announces Second Quarter 2026 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results ...
CareDx price target raised to $45 from $28 at BTIG
BTIG raised the firm’s price target on CareDx (CDNA) to $45 from $28 and keeps a Buy rating on the shares. The firm notes shares of CareDx are up 25%…
Craig-Hallum ups CareDx price target after ‘quite favorable’ Medicare LCD
Craig-Hallum raised the firm’s price target on CareDx (CDNA) to $35 from $26 and keeps a Hold rating on the shares after MolDX issued the updated Local Coverage Decision for…
CareDx announces finalization of Medicare Local Coverage Determination process
CareDx (CDNA) announced the finalization of the Medicare Local Coverage Determination process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across...
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report fi...
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization o...
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful comp...
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx showcases precision medicine diagnostics at ATC 2026
CareDx (CDNA) announced its participation at the American Transplant Congress 2026, taking place June 20-24 in Boston, Massachusetts. Real-world clinical use and scientific advancements involving Allo...
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx announces second KOAR analysis published in JASN
The company states: “CareDx (CDNA) announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry, a landmark multi-center study, in the Journal of the American Socie...
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and an equity plan amendment, with all proposals approved by majority vote. No shareholder questions were received, and final vote results will be published by June 17, 2026.
CareDx Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a strategic shift to precision diagnostics, highlighted by the Naveris acquisition and divestiture of lab products. Key growth drivers include new MRD indications, AlloHeme's upcoming launch, and workflow optimization, with robust financial targets and operational improvements supporting long-term profitability.
CareDx Proxy statement: Proxy filing
CareDx filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.